A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 341-349

  Pacey, Simon ^a,b   Gore, Martin ^b   Chao, David ^c   Banerji, Udai ^a,b   Larkin, James ^b   Sarker, Sarah ^b   Owen, Karen ^d   Asad, Yasmin ^a   Raynaud, Florence ^a   Walton, Mike ^a   Judson, Ian ^a,b   Workman, Paul ^a   Eisen, Tim ^e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

17 AAG; HSP90 inhbitor; Melanoma; Phase II

Indexed keywords

TANESPIMYCIN;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; GASTROINTESTINAL SYMPTOM; HEADACHE; HICCUP; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; MALE; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RASH; SIDE EFFECT; SINUS BRADYCARDIA; SKIN BRUISING; TASTE DISORDER; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZOQUINONES; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; ENGLAND; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LACTAMS, MACROCYCLIC; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84856554767     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9493-4     Document Type: Article

References (46)

1. Eigentler TK, Caroli UM, Radny P et al (2003) Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759 (Pubitemid 37527210)
2. Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone: An open and shut case for treatment. Biochem J 410:439-453 (Pubitemid 351429015)
3. Neckers L, Neckers K (2005) Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics-an update. Expert Opin Emerg Drugs 10:137-149 (Pubitemid 40293075)
4. Workman P, Burrows F, Neckers L et al (2007) Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 1113:202-216 (Pubitemid 350015011)
5. Powers MV, Workman P (2007) Inhibitors of the heat shock response: Biology and pharmacology. FEBS Lett 581:3758-3769 (Pubitemid 47081010)
6. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P (2005) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11(19 Pt 1):7023-7032 (Pubitemid 41428762)
7. Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, Workman P (2008) An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino- 17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol 62(5):769-778
8. Solit DB, Zheng FF, Drobnjak M et al (2002) 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993 (Pubitemid 34517631)
9. Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KM, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E, Workman P (2007) In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 67(5):2206-2216 (Pubitemid 46424240)
10. Sharp SY, Prodromou C, Boxall K et al (2007) Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 6:1198-1211 (Pubitemid 46711983)
11. Banerji U, O'Donnell A, Scurr M et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-4161 (Pubitemid 46211321)
12. Solit DB, Ivy SP, Kopil C et al (2007) Phase I trial of 17- allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775-1782 (Pubitemid 46952945)
13. Workman P (2003) Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: Unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2:131-138
14. Moreno-Farre J, Asad Y, Pacey S et al (2006) Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17- DMAG in human plasma. Rapid Commun Mass Spectrom 20:2845-2850 (Pubitemid 44526620)
15. Pacey S, Walton M, Eisen T et al (2006) Validation and use of western blotting to measure pharmacodynamic endpoints in Cancer Research UK clinical trials of Heat Shock Protein (HSP90) inhibitors. Abstract A161. Presented at the NCRI meeting, Birmingham, UK
16. Smith V, Sausville EA, Camalier RF et al (2005) Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: Effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 56:126-137 (Pubitemid 40884268)
17. Burger AM, Fiebig HH, Stinson SF et al (2004) 17-(Allylamino)- 17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15:377-387 (Pubitemid 38526763)
18. Flaherty K, Puzanov I, Sosman J et al (2009) Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27:9000
19. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65(23):10686-10691 (Pubitemid 41713335)
20. Modi S, Stopeck AT, Gordon MS et al (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study. J Clin Oncol 25:5410-5417 (Pubitemid 350232217)
21. Davies H, Bignell GR, Cox C (2002) et al Mutations of the BRAF gene in human cancer. Nature 417:949-954 (Pubitemid 34716871)
22. Banerji U, Affolter A, Judson I,Marais R,Workman P (2008) BRAF and NRAS mutations in melanoma: Potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 7(4):737-739 (Pubitemid 351551026)
23. Nowakowski GS, McCollum AK, Ames MM et al (2006) A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12:6087-6093 (Pubitemid 44703773)
24. Gelmon KA, Eisenhauer EA, Harris AL et al (1999) Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development? J Natl Cancer Inst 91:1281-1287 (Pubitemid 29387569)
25. Michaelis LC, Ratain MJ (2007) Phase II trials published in 2002: A cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res 13:2400-2405 (Pubitemid 46698590)
26. Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166 (Pubitemid 30036349)
27. Richards JM, Gale D, Mehta N et al (1999) Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17:651-657 (Pubitemid 29075254)
28. Balch CM, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17, 600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634 (Pubitemid 32786275)
29. Manola J, Atkins M, Ibrahim J et al (2000) Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793
30. Gogas HJ, Kirkwood JM, Sondak VK (2007) Chemotherapy for metastatic melanoma: Time for a change? Cancer 109:455-464 (Pubitemid 46190953)
31. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10 (Pubitemid 19099520)
32. Therasse P (2002) Evaluation of response: New and standard criteria. Ann Oncol 13(Suppl 4):127-129 (Pubitemid 35363763)
33. Egorin MJ, Zuhowski EG, Rosen DM et al (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47:291-302 (Pubitemid 32640768)
34. Kamal A, Thao L, Sensintaffar J et al (2003) et al A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410 (Pubitemid 37187270)
35. Chung YL, Troy H, Banerji U et al (2003) Magnetic Resonence Spectroscopic Pharmacodynamic Markers of the Heat Shock Protien Inhibitor 17-Allyamino, 17-Demethoxygeldanamycin (17-AAG) in Human Colon Cancer Models. J Natl Cancer Inst 95:1624-1633 (Pubitemid 37455930)
36. Smith-Jones PM, Solit D, Afroze F et al (2006) Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET. J Nucl Med 47:793-796 (Pubitemid 46768442)
37. Taldone T, Gozman A, Maharaj R et al (2008) Targeting Hsp90: Small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8:370-374
38. Kefford R, Millwars M, Hersey P et al (2007) Phase 2 Trial of Tanespimycin (KOS-953), a Heat Shock Protein-90 (Hap90) Inhibitor in Patients with Metastatic Melanoma. J Clin Oncol 25:8558
39. Pacey S, Wilson R, Walton M et al (2007) A Phase I Trial Of The Heat Shock Protein 90 (HSP90) Inhibitor 17- Dimethylaminoethylamino-17- Demethoxygeldanamycin (17- DMAG, Alvespimycin) Administered Weekly. J Clin Oncol 25
40. Flaherty KT, Gore L, Avadhani A et al (2008) First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or QD. J Clin Oncol 26:2502
41. Solit DB, Osman I, Polsky D et al (2008) Phase II trial of 17- allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14:8302-8307
42. Korn EL, Liu PY, Lee SJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534 (Pubitemid 351264344)
43. Elfiky A, Saif MW, Beeram M et al (2008) BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol 26:2503
44. Sessa C, Sharma SK, Britten CD et al (2009) A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol 27:3532
45. Bryson JC, Infante JR, Ramanathan RK et al (2008) A phase 1 dose-escalation study for the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-4522. J Clin Oncol 26:14613
46. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, Workman P (2008) NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68(8):2850-2860 (Pubitemid 351556284)